What You Should Know
- Most people with chronic lymphocytic leukemia (CLL) are treated with daily pills and never need intensive treatments like a stem cell transplant or CAR T-cell therapy.
- Once in a while, CLL can change into a faster-growing lymphoma. This is called Richter’s transformation, and it’s the main situation where these rarer treatments come up.
- Warning signs can include fevers, drenching night sweats, and a lymph node (gland) that keeps getting bigger. CLL has nodes that get bigger also; the point in Richter’s is that it is very rapidly getting larger. It’s worth telling your doctor if you notice them.
- Doctors don’t have a consensus on the optimal treatment, or which intensive treatment is best in this situation, and that’s an honest, open question in the field, not a gap in any one doctor’s knowledge.
One advantage of being treated in the region is access to specialists who see a lot of CLL. Dr. Kevin Kelly, a hematologist at the University of Southern California, is upfront about how uncommon these situations are.
Read MoreWhen CLL Changes Into Something More Aggressive
Every so often, CLL can transform into a faster-growing, aggressive lymphoma, which is a different kind of blood cancer. Doctors call this Richter’s transformation, and it’s the main reason a patient might suddenly need more intensive treatment. Dr. Kelly explains what it can look like.“We see that sometimes in patients on the targeted therapy where they might present with fevers, night sweats, and an enlarging lymph gland,” he says. “And then when we do a biopsy, we see that the CLL cells have transformed to more aggressive, larger cells.”
Those symptoms- fever, heavy night sweats, and a lymph node that keeps swelling are worth reporting to your care team promptly. They don’t always mean transformation. But they’re worth checking.
Stem Cell Transplant and CAR T
When Richter’s transformation occurs, your care team may consider different treatment options to keep CLL under control. A lymph node biopsy helps confirm Richter’s transformation.
According to the National Comprehensive Cancer Network (NCCN) and standard practice, patients first receive induction treatment — preferably on a clinical trial, or with chemoimmunotherapy — with allogeneic transplant considered as consolidation for those who achieve an objective response.
AlloSCT is recommended for patients who respond to induction therapy and are fit for transplant; it is not a standalone alternative to drug therapy.
The 2025 American Society for Transplantation and Cellular Therapy (ASTCT) guideline notes that whether CAR-T or allo-SCT is the better choice for chemoresponsive Richter’s transformation hasn’t been tested in prospective, head-to-head studies, and recommends clinical trial enrollment whenever possible.
Richter’s transformation calls for aggressive treatment because, left undertreated, it’s brutal: when Richter’s arises clonally from the underlying CLL (the most common scenario), median overall survival has historically been around one year — compared to roughly 9 years for de novo diffuse large B-cell lymphoma, the same cancer type without a CLL history. That stark gap is why doctors move quickly toward induction therapy, and why transplant or CAR-T are considered even though they’re intensive: for this disease, undertreating carries real risk.
A stem cell transplant replaces a patient’s blood-forming cells with healthy cells from a donor. When the cells come from a donor, doctors call it an “allogeneic” transplant, sometimes shortened to “allo.” It’s an intensive treatment, and Dr. Kelly says it’s often the aim for these patients.
“We often really try to go for a stem cell transplant for those patients,” he says.
The other option is CAR T-cell therapy. In this treatment, a patient’s own immune cells, called T cells, are collected, re-engineered in a lab to recognize and attack the cancer, and then given back to the patient.
Here’s where Dr. Kelly is refreshingly honest: doctors don’t yet have a clear answer on which of the two is the better choice.
“It’s a little bit up in the air at the moment whether you would do CAR T versus allotransplant for these patients who have Richter’s transformation,” he says.
That uncertainty isn’t a weakness in your doctor’s knowledge. It’s a real question that specialists are still working through. It’s also a good reason, if you ever face this, to seek care at, or at least a second opinion from, one of Southern California’s major academic medical centers, where teams handle these uncommon cases regularly. Dr. Kelly practices at one of them.
The Bigger Picture
It’s worth saying again: these are the exceptions, not the rule. Dr. Kelly is genuinely excited about newer approaches on the horizon, including immune-based treatments for patients whose disease has transformed.
“We’re also quite excited about the potential of immunotherapy … particularly patients who might’ve transformed to the more aggressive large cell lymphomas,” he says.
For the vast majority of people with CLL, day-to-day life means a pill and regular check-ups — not a transplant. Knowing these options exist and which symptoms to report is simply part of being an informed patient.
Learn more about SurvivorNet's rigorous medical review process.
